sb 203580 has been researched along with fingolimod hydrochloride in 1 studies
| Studies (sb 203580) | Trials (sb 203580) | Recent Studies (post-2010) (sb 203580) | Studies (fingolimod hydrochloride) | Trials (fingolimod hydrochloride) | Recent Studies (post-2010) (fingolimod hydrochloride) |
|---|---|---|---|---|---|
| 3,489 | 4 | 1,137 | 2,771 | 157 | 2,062 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Beppu, M; Kato, T; Masuko, K; Murata, M; Nakamura, H; Yudoh, K | 1 |
1 other study(ies) available for sb 203580 and fingolimod hydrochloride
| Article | Year |
|---|---|
Sphingosine-1-phosphate modulates expression of vascular endothelial growth factor in human articular chondrocytes: a possible new role in arthritis.
Topics: Aged; Cartilage, Articular; Cells, Cultured; Chondrocytes; Drug Interactions; Enzyme Inhibitors; Female; Fingolimod Hydrochloride; Flavonoids; Gene Expression; Humans; Imidazoles; Immunosuppressive Agents; Lysophospholipids; Male; Mitogen-Activated Protein Kinases; Osteoarthritis; Pertussis Toxin; Propylene Glycols; Pyridines; RNA, Messenger; Sphingosine; Vascular Endothelial Growth Factor A | 2012 |